您好,欢迎访问细胞应激生物学国家重点实验室(厦门大学) 设为首页 | 加入收藏

当前位置:首页  人才队伍  固定科研人员

邓贤明教授 博导
出处: 发布时间:2016-12-09 浏览次数:152


邓贤明 DENG Xianming, Ph.D.

邓贤明教授博导授,博士生导师                                

化学生物学和药物化学(Chemical Biology and Medicinal Chemistry Group

课题组组长

: +86-592-2184180

: +86-592-2181722

E-mail:xmdeng@xmu.edu.cn

Group web: http://121.192.179.196/lmpe/


2001年,厦门大学化学系化学专业,获理学学士学位;

2006年,中科院上海有机化学研究所有机化学专业,获理学博士学位;

2006年至2011年,哈佛医学院Dana-Farber癌症研究所,博士后研究;

201110月起,为厦门大学生命科学学院闽江学者特聘教授,微生物药物课题组学科带头人,入选中组部青年千人计划。


2001B.Sc., Xiamen University;

2006, Ph.D., Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Sciences.

2006-2011, Research Fellow, Dana-Farber Cancer Institute, Harvard Medical School.

2011.10-, Principal Investigator of Chemical Biology and Medicinal Chemistry Group, School of Life Sciences, Xiamen University.


主要研究领域(Research Area

化学生物学和药物化学。在化学生物学方面,我们集中于设计并合成新颖的针对蛋白激酶(Protein Kinase)和表观遗传蛋白(Epigenetic Enzyme)的小分子抑制剂,并运用这些功能小分子为工具,发现和解决信号传导通路、神经生物学和癌症中的新问题。在药物化学方面,以化学生物学研究成果为基础,结合传统的药物化学手段(构效关系研究、药代动力学和毒理学研究)进一步优化小分子工具化合物,以期发展针对癌症等相关疾病的靶向治疗药物。

Our research is focused on two major areas: chemical biology and medicinal chemistry. At the interface of chemistry and biology, we use organic synthesis to create new chemical tools for studying biological problems in human health and disease. These functional small-molecule tools are applied to control and elucidate cellular signal transduction in  cancer, stem cell, and neural diseases. Second, we pursue established medicinal chemistry approaches including structure activity relationship (SAR) study and pharmacokinetics modification to optimize pre-clinical drug candidates. We're working to address the following general questions: a) How can we develop small-molecule modulators with selectivity towards desired targets such as protein kinases and epigenetic enzymes? b) How can we use discovered-small-molecule tools to dissect the  molecular signaling pathways? c) How can we develop the 'lead' of targeted-drug from the tool compound?  


代表性论文(Selected publications* Co-first authorship

1.Kwiatkowski, N*; Deng, X.*; Wang, J.; Tan, L.; Villa, F.; Santaguida, S.; Huang, H. C.; Mitchison, T.; Musacchio, A.; Gray, N. Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen. ACS Chem. Biol.2012, 7, 185-96.

   Rated 'recommended' 6.0 by Faculty of 1000.

2.Deng, X.*; Dzamko, N.*; Prescott, A.; Davies, P.; Liu, Q.; Yang, Q.; Lee, J. D.; Patricelli, M. P.; Nomanbhoy, T. K.; Alessi, D. R.; Gray, N. S. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.Nat. Chem. Biol.2011, 7, 203-5.

   Rated 'recommended' 6.0 by Faculty of 1000.

3.Miduturu, C. V.*; Deng, X.*; Kwiatkowski, N.; Yang, W.; Brault, L.; Filippakopoulos, P.; Chung, E.; Yang, Q.; Schwaller, J.; Knapp, S.; King, R. W.; Lee, J. D.; Herrgard, S.; Zarrinkar, P.; Gray, N. S. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. Chem. Biol. 2011, 18, 868-79.

4.Deng, X.*; Wang, J.*; Zhang, J.*; Sim, T.; Kim, N. D.; Sasaki, T.; Luther, W., 2nd; George, R. E.; Janne, P. A.; Gray, N. S. Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors. ACS Med. Chem. Lett. 2011, 2, 379-384.

5.Deng, X.*; Yang, Q.*; Kwiatkowski, N.; Sim, T.; McDermott, U.; Settleman, J. E.; Lee, J. D.; Gray, N. S. Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1. ACS Med. Chem. Lett. 2011, 2, 195-200.

6.Yang, Q.*; Deng, X.*; Lu, B.*; Cameron, M.; Fearns, C.; Patricelli, M. P.; Yates, J. R., 3rd; Gray, N. S.; Lee, J. D. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 2010, 18, 258-67.

7.Deng, X.*; Okram, B.*; Ding, Q.*; Zhang, J.*; Choi, Y.; Adrian, F. J.; Wojciechowski, A.; Zhang, G.; Che, J.; Bursulaya, B.; Cowan-Jacob, S. W.; Rummel, G.; Sim, T.; Gray, N. S. Expanding the diversity of allosteric bcr-abl inhibitors.J. Med. Chem.2010, 53, 6934-46.

8.Deng, X.; Lim, S. M.; Zhang, J.; Gray, N. S. Broad spectrum alkynyl inhibitors of T315I Bcr-Abl.Bioorg. Med. Chem. Lett.2010, 20, 4196-200.

9.Zhang, J.; Adrian, F. J.; Jahnke, W.; Cowan-Jacob, S. W.; Li, A. G.; Iacob, R. E.; Sim, T.; Powers, J.; Dierks, C.; Sun, F.; Guo, G. R.; Ding, Q.; Okram, B.; Choi, Y.; Wojciechowski, A.; Deng, X.; Liu, G.; Fendrich, G.; Strauss, A.; Vajpai, N.; Grzesiek, S.; Tuntland, T.; Liu, Y.; Bursulaya, B.; Azam, M.; Manley, P. W.; Engen, J. R.; Daley, G. Q.; Warmuth, M.; Gray, N. S. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010, 463, 501-6.

10.Wang, Q.-G.; Deng, X.-M.; Zhu, B.-H.; Ye, L.-W.; Sun, X.-L.; Li, C.-Y.; Zhu, C.-Y.; Shen, Q.; Tang, Y. Tandem Michael addition/ylide epoxidation for the synthesis of highly functionalized cyclohexadiene epoxide derivatives. J. Am. Chem. Soc. 2008, 130, 5408-9.

11.Deng, X.-M.; Cai, P.; Ye, S.; Sun, X.-L.; Liao, W.-W.; Li, K.; Tang, Y.; Wu, Y.-D.; Dai, L.-X. Enantioselective synthesis of vinylcyclopropanes and vinylepoxides mediated by camphor-derived sulfur ylides: Rationale of enantioselectivity, scope, and limitation. J. Am. Chem. Soc.2006, 128, 9730-9740.

12.Deng, X. M.; Sun, X. L.; Tang, Y. Highly regioselective rearrangement of 2-substituted vinylepoxides catalyzed by gallium(III) triflate. J. Org. Chem.2005, 70, 6537-6540.

已申请的专利

1.Gray, N. S.; Zhang, J.; Okram, B.; Deng, X.; Chang, J.; Wojciechowski, A. PCT Int.  Appl. WO2009073153 .

2.Gray, N. S.; Deng, X.; Kwiatkowski, N. P. PCT Int. Appl. WO2010080712.

3.Gray, N. S.; Zhou, W.; Deng, X. PCT Int. Appl. WO2011115725.